Intellia Therapeutics, Inc.

LSE:0JBU Stock Report

Market Cap: US$1.5b

Intellia Therapeutics Valuation

Is 0JBU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0JBU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0JBU's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0JBU's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0JBU?

Key metric: As 0JBU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0JBU. This is calculated by dividing 0JBU's market cap by their current revenue.
What is 0JBU's PS Ratio?
PS Ratio33.8x
SalesUS$43.09m
Market CapUS$1.46b

Price to Sales Ratio vs Peers

How does 0JBU's PS Ratio compare to its peers?

The above table shows the PS ratio for 0JBU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.1x
GNS Genus
1.7x3.5%UK£1.1b
OXB Oxford Biomedica
4.5x21.0%UK£442.5m
BVXP Bioventix
14.4xn/aUK£195.7m
AVCT Avacta Group
7.9x0.4%UK£179.3m
0JBU Intellia Therapeutics
33.8x67.2%US$1.5b

Price-To-Sales vs Peers: 0JBU is expensive based on its Price-To-Sales Ratio (33.8x) compared to the peer average (7.1x).

Price to Sales Ratio vs Industry

How does 0JBU's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
GNS Genus
1.7x3.5%US$1.41b
OXB Oxford Biomedica
4.5x21.0%US$554.49m
TRX Tissue Regenix Group
1.6x15.1%US$50.88m
PBX ProBiotix Health
4.8xn/aUS$12.88m
0JBU 33.8xIndustry Avg. 8.1xNo. of Companies7PS020406080100+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0JBU is expensive based on its Price-To-Sales Ratio (33.8x) compared to the European Biotechs industry average (8.1x).

Price to Sales Ratio vs Fair Ratio

What is 0JBU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0JBU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio33.8x
Fair PS Ratio0.04x

Price-To-Sales vs Fair Ratio: 0JBU is expensive based on its Price-To-Sales Ratio (33.8x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0JBU forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$14.32
US$59.78
+317.5%
43.3%US$128.00US$14.00n/a27
Nov ’25US$14.82
US$64.33
+334.2%
46.1%US$144.00US$14.00n/a27
Oct ’25US$19.36
US$67.48
+248.6%
40.9%US$144.00US$24.00n/a27
Sep ’25US$22.10
US$69.12
+212.7%
40.1%US$144.00US$24.00n/a26
Aug ’25US$25.26
US$70.26
+178.1%
38.1%US$144.00US$24.00n/a26
Jul ’25US$22.32
US$70.26
+214.9%
38.1%US$144.00US$24.00n/a26
Jun ’25US$21.54
US$70.26
+226.2%
38.1%US$144.00US$24.00n/a26
May ’25US$22.60
US$71.16
+214.9%
38.0%US$144.00US$24.00n/a25
Apr ’25US$28.14
US$71.52
+154.1%
37.7%US$144.00US$24.00n/a25
Mar ’25US$33.46
US$70.40
+110.4%
37.4%US$144.00US$24.00n/a25
Feb ’25US$25.82
US$76.08
+194.7%
35.7%US$145.00US$29.00n/a25
Jan ’25US$30.81
US$76.36
+147.8%
36.0%US$145.00US$29.00n/a25
Dec ’24US$30.28
US$76.36
+152.2%
36.0%US$145.00US$29.00n/a25
Nov ’24US$25.40
US$83.04
+226.9%
34.5%US$157.00US$38.00US$14.8225
Oct ’24US$31.56
US$84.88
+168.9%
33.2%US$157.00US$38.00US$19.3625
Sep ’24US$37.82
US$83.58
+121.0%
33.5%US$157.00US$38.00US$22.1026
Aug ’24US$40.71
US$86.81
+113.2%
34.3%US$154.00US$44.00US$25.2626
Jul ’24US$40.83
US$87.19
+113.5%
34.2%US$154.00US$44.00US$22.3226
Jun ’24US$37.93
US$87.27
+130.1%
34.3%US$154.00US$44.00US$21.5426
May ’24US$38.10
US$92.57
+143.0%
36.7%US$168.00US$39.00US$22.6028
Apr ’24US$37.15
US$94.30
+153.8%
36.6%US$168.00US$39.00US$28.1427
Mar ’24US$40.55
US$95.62
+135.8%
36.3%US$168.00US$39.00US$33.4626
Feb ’24US$41.95
US$103.65
+147.1%
35.2%US$167.00US$39.00US$25.8226
Jan ’24US$34.31
US$108.12
+215.1%
34.4%US$173.00US$48.00US$30.8126
Dec ’23US$45.94
US$109.70
+138.8%
33.1%US$173.00US$48.00US$30.2827
Nov ’23US$52.89
US$116.05
+119.4%
36.5%US$207.00US$50.00US$25.4027

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

Formycon

€827.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€47.10

7D

4.0%

1Y

-23.5%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

7D

-1.7%

1Y

-6.3%